

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01630		SERIAL NO.: 10/667,856	
INFORMATION DISCLOSURE STATEMENT FOR PATENT (Use several sheets if necessary)				APPLICANT: Courtney and Laughlin			
				FILING DATE: September 22, 2003		GROUP: 1617	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KS	AA	Ezzet <i>et al.</i> , "The pharmacokinetics of posaconazole in neutropenic oncology patients," <i>Abstract from the 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Illinois, USA; September 22-25, 2001, 41:4 (2001).</i>					
KS	AB	Mellinghoff <i>et al.</i> , "Use of posaconazole (SCH56592) for treatment of invasive fungal infections refractory to standard antifungal therapy" (Abstract from the 42 nd Annual Meeting of the American Society of Hematology; San Francisco, California, USA; December 01-05, 2000), <i>Blood, 96(11 Part 2):341b (2000).</i>					
KS	AC	Skiest <i>et al.</i> , "Treatment of azole-refractory candidiasis in HIV disease," <i>Abstract from the 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, California, USA; September 26-29, 1999, 39:489 (1999).</i>					
KS	AD	Petratiene <i>et al.</i> , "Correlation between serum galactomannan concentrations and antifungal efficacy of posaconazole (SCH 56592) in treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits," <i>Abstract from the 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada; September 17-20, 2000, 40:380-381 (2000).</i>					
KS	AE	Connolly <i>et al.</i> , "Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice," <i>Antimicrobial Agents and Chemotherapy, 44(10):2604-2608 (2000).</i>					
EXAMINER		DATE CONSIDERED					
Kantamuni Sdeh		12/12/06					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							